Skip to main content

Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients With Metastatic or Surgically Unresectable Urothelial Carcinoma and Selected FGFR Gene Alterations - the Phase 3 THOR Study

1 star
Loriot
Yohann
Medical Oncology
Institut Gustave Roussy
Villejuif
France
Show all authors
Maroto Rey
Jose Pablo
Medical Oncology
Hospital de la Santa Creu i Sant Pau
Barcelona
Spain
Necchi
Andrea
Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan
Italy
Park
Se Hoon
Medicine
Samsung Medical Center
Seoul
Korea
Huddart
Robert
Clinical Academic Radiotherapy
Institute of Cancer Research, Sutton
London
United Kingdom
Burgess
Earle
Medical Oncology
Levine Cancer Institute, Carolinas HealthCare System
Charlotte
North Carolina
Zhong
Bob
Biostatistics
Janssen Research & Development
Spring House
Pennsylvania
United States
Santiago-Walker
Ademi
Translational Research
Janssen Research & Development
Spring House
Pennsylvania
United States
Little
Shonda
Clinical Oncology
Janssen Research & Development
Spring House
Pennsylvania
United States
Roccia
Tito
Clinical Development and Medical Affairs
Janssen Research & Development
Buckinghamshire
United Kingdom
De Porre
Peter
Global Medical Affairs
Janssen Research & Development
Beerse
Belgium
Siefker-Radtke
Arlene
Genitourinary Medical Oncology
University of Texas, MD Anderson Cancer Center
Houston
Texas
United States

Tabs

Speciality: 
Oncology (medical)
Keywords: 
trial in progress, phase 3, urothelial carcinoma, erdafitinib